In many human neurological and psychiatric disorders such as chronic pain,anxiety and seizures, potassium chloride membrane protein KCC2 activity isreduced. A study published this week in "Nature Medicine" on the discovery,a new monoclonal antibody can enhance the activity of KCC2 development and ease the chronic pain in rats. This finding implies that the treatment of painand other due to decreased the activity of KCC2 and the disease has a potential therapeutic approach.
KCC2 is a transmembrane pump, can make the concentration of chloride ion in nerve cells remained at a low level, thereby inhibiting nerve impulses.Therefore, Yves De Koninck et al conclude, drugs that activate the KCC2might also be from the clinical level repair inhibition signal and treatment of neurological diseases. They screened a kind of immobilized papain compound library and define a kind of their CLP257 drugs.
Then, the researchers further found that this drug can enhance the expression and activity of KCC2, and reduce the pain of nerve injury in rats.They noticed a related compound more than CLP257 in pharmacology,drug pregabalin the compounds in alleviating pain in rats with existing a kind of pain has the same effect, but not like pregabalin on the motor side effects of excess.
Cusabio has a sound platform for the development of elisa kit http://www.cusabio.com/pro_7.html, mature antigen-antibody research and development system. We are proficient in a variety of ELISA technologIies, such as the double-antibody sandwich method, double antigen sandwich method, (direct) competition ELISA, indirect competition ELISA, blocking method, indirect ELISA and other methods. Combined with diagnostic kits development team, we are able to develop the kits with clinical diagnostic level, and make the quality in the leading place worldwide